Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Risk categories predict mRCC survival

Rini B et al. Clin Genitourin Cancer. 2018 May 3. doi: 10.1016/j.clgc.2018.04.005.

Key clinical point: The IMDC model is prognostic for responses and survival in patients with mRCC treated with sunitinib.

Major finding: Median progression-free survival for favorable, intermediate, and poor-risk patients was 14.1, 10.7, and 2.4 months, respectively.

Study details: Retrospective analysis of 375 sunitinib-treated patients in a randomized clinical trial.

Disclosures: Medical writing for the study was supported by Pfizer. Dr. Rini and his coauthors disclosed research funding and/or consulting fees from Pfizer and other companies. Four of the coauthors are Pfizer employees and stockholders.

Source: Rini B et al. Clin Genitourin Cancer. 2018 May 3. doi: 10.1016/j.clgc.2018.04.005.

Read the article.

Citation:

Rini B et al. Clin Genitourin Cancer. 2018 May 3. doi: 10.1016/j.clgc.2018.04.005.

This Week's Must Reads

Broad opioid legislation advances in Congress, Senate floor debate, Sept. 17, 2018

Early supportive care cuts costs related to curative treatment, Koprowski CD et al. 2018 ASCO Quality Care Symposium, Abstract 142

Employee deductibles outstrip wages, Kaiser Family Foundation, 2018 Employer Health Benefits

The financial burden of metastatic breast cancer, Wheeler SB et al. Quality Care Symposium, Abstract 32

Must Reads in Renal Cell Carcinoma

Obesity tied to higher risk of clear cell RCC, Callahan CL et al. Cancer Epidemiol. 2018 Jul 18. doi: 10.1016/j.canep.2018.07.002

Partial nephrectomy for localized RCC, Cahn D et al. AUA Annual Meeting, Abstract PD07-04

RFA for small renal tumors holds up over long term, Johnson B et al. J Urol. 2018. doi: 10.1016/j.juro.2018.08.045

Pazopanib active in von Hippel-Lindau disease neoplasms, Jonasch E et al. Lancet Oncol. 2018 Sep 17. doi: 10.1016/S1470-2045(18)30487-X

Improved RCC survival attributed to better therapy, not earlier diagnosis, Patel HD et al. Eur Urol Oncol. 2018 Sep 25. doi: 10.1016/j.euo.2018.08.023